English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The hepatitis C virus (HCV) genotype-specific impacts on the host metabolic alterations remained inconclusive.    Methods  A prospective study including 229 (118 genotype 1 (G1) and 111 G2) consecutive chronic HCV patients who had completed a course of anti-HCV treatment and underwent pre- and 24 weeks post-treatment surveys of metabolic profiles was conducted. Patients were stratified according to the therapeutic response, viral genotype and baseline insulin resistance (IR: homeostasis model assessments of IR (HOMA-IR) ≥2.5). Paired t-tests were used to compare the pre- and post-treatment variables.    Results  Significant post-therapeutic increases in cholesterol, triglyceride, HDL, LDL, apolipoprotein A1 and apolipoprotein B were observed in patients with sustained virological response (SVR) but not in those without. Among those with SVR, post-therapeutic increases in HDL ( p<0.001 ) and apolipoprotein A1 ( p  = 0.012) were only found in G2, whereas increased triglyceride/HDL ( p  = 0.01) ratios were only found in G1 patients. When stratified by baseline IR among those with SVR, a significant increase in post-treatment HDL ( p  = 0.019) and apolipoprotein A1 ( p  = 0.012) but a decrease in HOMA-IR ( p  = 0.04), C-peptide ( p  = 0.019) and hemoglobin A1c ( p  = 0.047) were found in patients with baseline IR; a significant increase in HOMA-IR ( p  = 0.002) was found in patients without baseline IR. The latter change was observed only in G1 ( p  = 0.01) but not G2 patients. Although the pre-treatment metabolic profiles of G1 and G2 patients were indifferent, G1 had higher post-treatment triglyceride/HDL ratios ( p  = 0.041) and triglyceride ( p  = 0.044) levels than G2 patients.    Conclusions  G2 benefit more than G1 patients from viral clearance in metabolic alterations, particularly in those without baseline IR.

Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance